These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36093650)

  • 1. Unfavorable prognosis and clinical consequences of APOBEC3B expression in breast and other cancers: A systematic review and meta-analysis.
    Jafarpour S; Yazdi M; Nedaeinia R; Ghobakhloo S; Salehi R
    Tumour Biol; 2022; 44(1):153-169. PubMed ID: 36093650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer.
    Kim SH; Ahn S; Suh KJ; Kim YJ; Park SY; Kang E; Kim EK; Kim IA; Chae S; Choi M; Kim JH
    Breast Cancer Res Treat; 2020 Oct; 183(3):697-704. PubMed ID: 32715441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.
    Liu J; Sieuwerts AM; Look MP; van der Vlugt-Daane M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
    PLoS One; 2016; 11(8):e0161731. PubMed ID: 27552096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers.
    Sieuwerts AM; Willis S; Burns MB; Look MP; Meijer-Van Gelder ME; Schlicker A; Heideman MR; Jacobs H; Wessels L; Leyland-Jones B; Gray KP; Foekens JA; Harris RS; Martens JW
    Horm Cancer; 2014 Dec; 5(6):405-13. PubMed ID: 25123150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers.
    Tsuboi M; Yamane A; Horiguchi J; Yokobori T; Kawabata-Iwakawa R; Yoshiyama S; Rokudai S; Odawara H; Tokiniwa H; Oyama T; Takeyoshi I; Nishiyama M
    Breast Cancer; 2016 Sep; 23(5):780-8. PubMed ID: 26476745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation.
    Cescon DW; Haibe-Kains B; Mak TW
    Proc Natl Acad Sci U S A; 2015 Mar; 112(9):2841-6. PubMed ID: 25730878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant APOBEC3B Expression in Breast Cancer Is Linked to Proliferation and Cell Cycle Phase.
    Roelofs PA; Timmermans MAM; Stefanovska B; den Boestert MA; van den Borne AWM; Balcioglu HE; Trapman AM; Harris RS; Martens JWM; Span PN
    Cells; 2023 Apr; 12(8):. PubMed ID: 37190094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of APOBEC3B mRNA in Primary Breast Cancer of Japanese Women.
    Tokunaga E; Yamashita N; Tanaka K; Inoue Y; Akiyoshi S; Saeki H; Oki E; Kitao H; Maehara Y
    PLoS One; 2016; 11(12):e0168090. PubMed ID: 27977754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APOBEC3B promotes hepatocarcinogenesis and metastasis through novel deaminase-independent activity.
    Ma W; Ho DW; Sze KM; Tsui YM; Chan LK; Lee JM; Ng IO
    Mol Carcinog; 2019 May; 58(5):643-653. PubMed ID: 30575099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.
    Caswell DR; Gui P; Mayekar MK; Law EK; Pich O; Bailey C; Boumelha J; Kerr DL; Blakely CM; Manabe T; Martinez-Ruiz C; Bakker B; De Dios Palomino Villcas J; I Vokes N; Dietzen M; Angelova M; Gini B; Tamaki W; Allegakoen P; Wu W; Humpton TJ; Hill W; Tomaschko M; Lu WT; Haderk F; Al Bakir M; Nagano A; Gimeno-Valiente F; de Carné Trécesson S; Vendramin R; Barbè V; Mugabo M; Weeden CE; Rowan A; McCoach CE; Almeida B; Green M; Gomez C; Nanjo S; Barbosa D; Moore C; Przewrocka J; Black JRM; Grönroos E; Suarez-Bonnet A; Priestnall SL; Zverev C; Lighterness S; Cormack J; Olivas V; Cech L; Andrews T; Rule B; Jiao Y; Zhang X; Ashford P; Durfee C; Venkatesan S; Temiz NA; Tan L; Larson LK; Argyris PP; Brown WL; Yu EA; Rotow JK; Guha U; Roper N; Yu J; Vogel RI; Thomas NJ; Marra A; Selenica P; Yu H; Bakhoum SF; Chew SK; Reis-Filho JS; Jamal-Hanjani M; Vousden KH; McGranahan N; Van Allen EM; Kanu N; Harris RS; Downward J; Bivona TG; Swanton C
    Nat Genet; 2024 Jan; 56(1):60-73. PubMed ID: 38049664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DNA deaminase APOBEC3B interacts with the cell-cycle protein CDK4 and disrupts CDK4-mediated nuclear import of Cyclin D1.
    McCann JL; Klein MM; Leland EM; Law EK; Brown WL; Salamango DJ; Harris RS
    J Biol Chem; 2019 Aug; 294(32):12099-12111. PubMed ID: 31217276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated Analysis Reveals That Long Non-Coding RNA TUBA4B Can Be Used as a Prognostic Biomarker in Various Cancers.
    Zhang T; Wu DM; Deng SH; Han R; Liu T; Li J; Xu Y
    Cell Physiol Biochem; 2018; 49(2):530-544. PubMed ID: 30157490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells.
    Yamazaki H; Shirakawa K; Matsumoto T; Hirabayashi S; Murakawa Y; Kobayashi M; Sarca AD; Kazuma Y; Matsui H; Maruyama W; Fukuda H; Shirakawa R; Shindo K; Ri M; Iida S; Takaori-Kondo A
    Sci Rep; 2019 May; 9(1):7122. PubMed ID: 31073151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression.
    Yamazaki H; Shirakawa K; Matsumoto T; Kazuma Y; Matsui H; Horisawa Y; Stanford E; Sarca AD; Shirakawa R; Shindo K; Takaori-Kondo A
    PLoS One; 2020; 15(1):e0223463. PubMed ID: 31914134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells.
    Periyasamy M; Singh AK; Gemma C; Kranjec C; Farzan R; Leach DA; Navaratnam N; Pálinkás HL; Vértessy BG; Fenton TR; Doorbar J; Fuller-Pace F; Meek DW; Coombes RC; Buluwela L; Ali S
    Nucleic Acids Res; 2017 Nov; 45(19):11056-11069. PubMed ID: 28977491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change of Circulating and Tissue-Based miR-20a in Human Cancers and Associated Prognostic Implication: A Systematic Review and Meta-Analysis.
    Zhang Q; Wang Q; Sun W; Gao F; Liu L; Cheng L; Li Z
    Biomed Res Int; 2018; 2018():6124927. PubMed ID: 30596096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of TSP-1 as prognostic marker in various cancers: a systematic review and meta-analysis.
    Sun S; Dong H; Yan T; Li J; Liu B; Shao P; Li J; Liang C
    BMC Med Genet; 2020 Jun; 21(1):139. PubMed ID: 32600280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of APOBEC3A and 3B expression in patients with breast cancer.
    Kim YS; Sun S; Yoon JS; Ko YH; Won HS; Kim JS
    PLoS One; 2020; 15(3):e0230261. PubMed ID: 32176735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein kinase A inhibits tumor mutator APOBEC3B through phosphorylation.
    Matsumoto T; Shirakawa K; Yokoyama M; Fukuda H; Sarca AD; Koyabu S; Yamazaki H; Kazuma Y; Matsui H; Maruyama W; Nagata K; Tanabe F; Kobayashi M; Shindo K; Morishita R; Sato H; Takaori-Kondo A
    Sci Rep; 2019 Jun; 9(1):8307. PubMed ID: 31165764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of AGR2 expression in solid tumours: a systematic review and meta-analysis.
    Tian SB; Tao KX; Hu J; Liu ZB; Ding XL; Chu YN; Cui JY; Shuai XM; Gao JB; Cai KL; Wang JL; Wang GB; Wang L; Wang Z
    Sci Rep; 2017 Nov; 7(1):15500. PubMed ID: 29138453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.